Skip to main navigation Skip to search Skip to main content

HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper

  • S. Fidler
  • , S. Lewin
  • , S. Deeks
  • , O. S. Sogaard
  • , L. Vanderkerckhove
  • , S. Collins
  • , D. Kelly
  • , J. Singh
  • , M. Caskey
  • , J. Frater

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.

Original languageEnglish
Article number100025
JournalJournal of Virus Eradication
Volume7
Issue number1
DOIs
StatePublished - Mar 2021
Externally publishedYes

Keywords

  • Analytical treatment interruption (ATI) COVID-19
  • HIV cure
  • SARS-CoV-2

Fingerprint

Dive into the research topics of 'HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper'. Together they form a unique fingerprint.

Cite this